SillaJen Current Assets

What does SillaJen do? SillaJen, Inc. generates revenue through the development and commercialization of oncolytic immunotherapeutics, primarily focusing on viral therapies for cancer treatment. The company's major product, Pexa-Vec, is currently in a global Phase 3 clinical trial for liver cancer treatment, while additional oncolytic virus immunotherapeutics such as SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963 are also part of its portfolio. These products target oncology segments, particularly liver cancer, and are developed for potential use in clinical settings. SillaJen's revenue streams are derived from the progression of these therapies through clinical trials and eventual market entry, with Pexa-Vec representing the most advanced product in its pipeline. The company's product portfolio includes multiple oncolytic virus immunotherapeutics, each identified by specific codes such as SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963, which are designed for various cancer treatments. Pexa-Vec, the lead candidate, is in Phase 3 trials for liver cancer, indicating a focus on advanced-stage oncology solutions. These products are developed for pharmaceutical and biotech companies seeking innovative cancer therapies, with the primary target being liver cancer patients in clinical trials. SillaJen's business model relies on the successful advancement of these clinical trials to secure partnerships or direct sales in the oncology market. SillaJen's revenue is tied to the clinical development and potential commercialization of its oncolytic virus immunotherapeutics. The company's pipeline includes Pexa-Vec, which is in a global Phase 3 clinical trial for liver cancer, and other products like SJ-102, SJ-103, SJ-815, JX-929, JX-930, and JX-963, which are part of its broader portfolio. These products are intended for use in oncology treatments, particularly targeting liver cancer. The company's focus on advancing these therapies through clinical stages positions it to generate revenue through partnerships or direct sales once the products are approved and marketed. SillaJen is one of the most popular companies on Eulerpool.